Changes in Beneficial Ownership · 4
bioAffinity Technologies, Inc.
BIAFNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
primary_doc.xml
Filing details
- Report period
- 2026-09-22
- Issuer
- bioAffinity Technologies, Inc.
- Issuer CIK
- 0001712762
- Trading symbol
- BIAF
- No longer subject to Section 16
- Checked
Reporting owner 1
- Name
- HRT FINANCIAL LP
- Reporting owner CIK
- 0001475597
- Relationship
- 10% owner
- Address
- 3 WORLD TRADE CENTER, 175 GREENWICH STRE, 76TH FLOOR, NEW YORK, NY, 10007
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-09-22 | P · Form 4 | 18,929 | A | 8.5879[F1] | 126,519[F8] | D |
| Common Stock | 2026-09-22 | S · Form 4 | 7,077 | D | 8.6306[F2] | 126,519[F8] | D |
| Common Stock | 2026-09-23 | P · Form 4 | 7,509 | A | 7.9123[F3] | 128,884[F8] | D |
| Common Stock | 2026-09-23 | P · Form 4 | 11,002 | A | 8.1438[F4] | 128,884[F8] | D |
| Common Stock | 2026-09-23 | S · Form 4 | 11,129 | D | 7.9399[F5] | 128,884[F8] | D |
| Common Stock | 2026-09-23 | S · Form 4 | 10,859 | D | 8.1074[F6] | 128,884[F8] | D |
| Common Stock | 2026-09-24 | P · Form 4 | 30,065 | A | 7.668[F9] | 131,221[F14] | D |
| Common Stock | 2026-09-24 | S · Form 4 | 27,246 | D | 7.755[F10] | 131,221[F14] | D |
| Common Stock | 2026-09-25 | P · Form 4 | 7,271 | A | 7.8065[F11] | 126,037[F14] | D |
| Common Stock | 2026-09-25 | S · Form 4 | 9,111 | D | 7.8588[F12] | 126,037[F14] | D |
| Common Stock | 2026-09-28 | P · Form 4 | 10,734 | A | 7.6438[F15] | 127,533[F23] | D |
| Common Stock | 2026-09-28 | P · Form 4 | 2 | A | 8.09 | 127,533[F23] | D |
| Common Stock | 2026-09-28 | S · Form 4 | 13,856 | D | 7.5676[F16] | 127,533[F23] | D |
| Common Stock | 2026-09-28 | S · Form 4 | 152 | D | 8.1012[F17] | 127,533[F23] | D |
| Common Stock | 2026-09-29 | P · Form 4 | 8,894 | A | 6.8647[F18] | 134,741[F23] | D |
| Common Stock | 2026-09-29 | P · Form 4 | 13,840 | A | 7.1206[F19] | 134,741[F23] | D |
| Common Stock | 2026-09-29 | S · Form 4 | 18,627 | D | 6.8259[F20] | 134,741[F23] | D |
| Common Stock | 2026-09-29 | S · Form 4 | 2,201 | D | 7.0518[F21] | 134,741[F23] | D |
| Common Stock | 2026-09-30 | P · Form 4 | 12,125 | A | 6.7775[F24] | 126,146[F28] | D |
| Common Stock | 2026-09-30 | S · Form 4 | 20,432 | D | 6.7638[F25] | 126,146[F28] | D |
| Common Stock | 2026-10-01 | P · Form 4 | 17,873 | A | 6.5436[F26] | 116,658[F29] | D |
| Common Stock | 2026-10-01 | S · Form 4 | 41,529 | D | 6.4466[F27] | 116,658[F29] | D |
Table key
- P · Form 4
- Purchase on the market or privately
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant (rights to buy) | 3,645[F7] | 2026-09-23 | P · Form 4 | 1 | A | 0.32 | 2022-06-22 | 2027-06-22 | Common Stock | 0.0022 | 1,198[F8] | D |
| Warrant (rights to buy) | 3,645[F7] | 2026-09-23 | S · Form 4 | 2 | D | 0.31 | 2022-06-22 | 2027-06-22 | Common Stock | 0.0044 | 1,198[F8] | D |
| Warrant (rights to buy) | 3,645[F13] | 2026-09-24 | S · Form 4 | 6 | D | 0.26 | 2022-06-22 | 2027-06-22 | Common Stock | 0.0133 | 1,202[F14] | D |
| Warrant (rights to buy) | 3,645[F13] | 2026-09-25 | S · Form 4 | 1 | D | 0.26 | 2022-06-22 | 2027-06-22 | Common Stock | 0.0022 | 1,202[F14] | D |
| Warrant (rights to buy) | 3,645[F22] | 2026-09-28 | P · Form 4 | 2 | A | 0.38 | 2022-06-22 | 2027-06-22 | Common Stock | 0.0044 | 913[F23] | D |
| Warrant (rights to buy) | 3,645[F22] | 2026-09-29 | P · Form 4 | 1 | A | 0.32 | 2022-06-22 | 2027-06-22 | Common Stock | 0.0022 | 986[F23] | D |
Table key
- P · Form 4
- Purchase on the market or privately
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Footnotes
- F1
- Weighted average price; executed in multiple trades at prices from $8.405 to $8.74.*↩ 1
- F2
- Weighted average price; executed in multiple trades at prices from $8.405 to $8.74.*↩ 1
- F3
- Weighted average price; executed in multiple trades at prices from $7.78 to $7.995.*↩ 1
- F4
- Weighted average price; executed in multiple trades at prices from $8.00 to $8.80.*↩ 1
- F5
- Weighted average price; executed in multiple trades at prices from $7.86 to $7.99.*↩ 1
- F6
- Weighted average price; executed in multiple trades at prices from $8.00 to $8.84.*↩ 1
- F7
- Each warrant is exercisable for 1/450 of a share of Common Stock; the exercise price shown is per whole share, as adjusted for the issuer's reverse stock splits. Underlying amounts are rounded to four decimal places.↩ 1↩ 2
- F8
- Represents the reporting person's beneficial ownership at the end of the transaction date, after all transactions on that date, including transactions not reported on this form.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8
- F9
- Weighted average price; executed in multiple trades at prices from $7.50 to $7.95.*↩ 1
- F10
- Weighted average price; executed in multiple trades at prices from $7.59 to $7.98.*↩ 1
- F11
- Weighted average price; executed in multiple trades at prices from $7.67 to $7.95.*↩ 1
- F12
- Weighted average price; executed in multiple trades at prices from $7.74 to $7.96.*↩ 1
- F13
- Each warrant is exercisable for 1/450 of a share of Common Stock; the exercise price shown is per whole share, as adjusted for the issuer's reverse stock splits. Underlying amounts are rounded to four decimal places.↩ 1↩ 2
- F14
- Represents the reporting person's beneficial ownership at the end of the transaction date, after all transactions on that date, including transactions not reported on this form.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6
- F15
- Weighted average price; executed in multiple trades at prices from $7.33 to $7.93.*↩ 1
- F16
- Weighted average price; executed in multiple trades at prices from $7.33 to $7.92.*↩ 1
- F17
- Weighted average price; executed in multiple trades at prices from $8.10 to $8.13.*↩ 1
- F18
- Weighted average price; executed in multiple trades at prices from $6.68 to $6.99.*↩ 1
- F19
- Weighted average price; executed in multiple trades at prices from $7.01 to $7.50.*↩ 1
- F20
- Weighted average price; executed in multiple trades at prices from $6.69 to $6.99.*↩ 1
- F21
- Weighted average price; executed in multiple trades at prices from $7.00 to $7.60.*↩ 1
- F22
- Each warrant is exercisable for 1/450 of a share of Common Stock; the exercise price shown is per whole share, as adjusted for the issuer's reverse stock splits. Underlying amounts are rounded to four decimal places.↩ 1↩ 2
- F23
- Represents the reporting person's beneficial ownership at the end of the transaction date, after all transactions on that date, including transactions not reported on this form.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8↩ 9↩ 10
- F24
- Weighted average price; executed in multiple trades at prices from $6.56 to $6.99.*↩ 1
- F25
- Weighted average price; executed in multiple trades at prices from $6.59 to $6.99.*↩ 1
- F26
- Weighted average price; executed in multiple trades at prices from $6.23 to $6.88.*↩ 1
- F27
- Weighted average price; executed in multiple trades at prices from $6.07 to $6.865.*↩ 1
- F28
- Represents the reporting person's beneficial ownership at the end of the transaction date, after all transactions on that date, including transactions not reported on this form.↩ 1↩ 2
- F29
- Represents the reporting person's beneficial ownership immediately after the transaction that reduced its beneficial ownership to 10% or less of the outstanding Common Stock, ending the period in which the transactions reported on this line occurred, including transactions not reported on this form.↩ 1↩ 2
Remarks
*The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected.
Signature 1
- Signed
- Adam Nunes
- Date
- 2026-11-19
Company context
bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung, is a non-invasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.